Mutation_NN in_IN 23S_JJ rRNA_NP Associated_NP with_IN Macrolide_NP Resistance_NP in_IN Neisseria_NP gonorrhoeae_NNS Fifty-six_NP azithromycin-resistant_NP (_( MICs_NP ,_, 2.0_CD to_TO 4.0_CD mug/ml_NN )_) Neisseria_NP gonorrhoeae_NNS strains_NNS with_IN cross-resistance_NN to_TO erythromycin_NN (_( MICs_NP ,_, 2.0_CD to_TO 64.0_CD mug/ml_NN )_) ,_, isolated_VBN in_IN Canada_NP between_IN 1997_CD and_CC 1999_CD ,_, were_VBD characterized_VBN ,_, and_CC their_PP$ mechanisms_NNS of_IN azithromycin_NN resistance_NN were_VBD determined_VBN ._SENT Most_RBS (_( 58.9_CD %_NN )_) of_IN them_PP belonged_VBD to_TO auxotype-serotype_NN class_NN NR/IB-03_NP ,_, with_IN a_DT 2.6-mDa_JJ plasmid_NN ._SENT Based_VBN on_IN resistance_NN to_TO crystal_NN violet_NN (_( MICs_NP >=_NN 1_CD mug/ml_NN )_) ,_, 96.4_CD %_NN of_IN these_DT macrolide-resistant_JJ strains_NNS appeared_VBD to_TO have_VB increased_VBN efflux_NN ._SENT Nine_CD of_IN the_DT eleven_NN strains_NNS selected_VBN for_IN further_JJR characterization_NN were_VBD found_VBN to_TO have_VB a_DT promoter_NN region_NN mtrR_NP mutation_NN ,_, a_DT single-base-pair_NN (_( A_NP )_) deletion_NN in_IN the_DT 13-bp_JJ inverted_JJ repeat_NN ,_, which_WDT is_VBZ believed_VBN to_TO cause_VB overexpression_NN of_IN the_DT mtrCDE-encoded_JJ efflux_NN pump_NN ._SENT The_DT two_CD remaining_VBG macrolide-resistant_JJ strains_NNS (_( erythromycin_NN MIC_NP ,_, 64.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 4.0_CD mug/ml_NN )_) ,_, which_WDT did_VBD not_RB have_VB the_DT mutation_NN in_IN the_DT mtrR_NP promoter_NN region_NN ,_, were_VBD found_VBN to_TO have_VB a_DT C2611T_NP mutation_NN (_( Escherichia_NP coli_NNS numbering_VBG )_) in_IN the_DT peptidyltransferase_NN loop_NN in_IN domain_NN V_NN of_IN the_DT 23S_JJ rRNA_NN alleles_NNS ._SENT Although_IN mutations_NNS in_IN domain_NN V_NN of_IN 23S_JJ rRNA_NN alleles_NNS had_VBD been_VBN reported_VBN in_IN other_JJ bacteria_NNS ,_, including_VBG E._NP coli_NNS ,_, Streptococcus_NP pneumoniae_NNS ,_, and_CC Helicobacter_NP pylori_NNS ,_, this_DT is_VBZ the_DT first_JJ observation_NN of_IN these_DT mutations_NNS associated_VBN with_IN macrolide_NN resistance_NN in_IN N._NP gonorrhoeae_NNS ._SENT Erythromycin_NN is_VBZ sometimes_RB used_VBN to_TO treat_VB gonorrhea_NN if_IN a_DT patient_NN has_VBZ a_DT cephalosporin_NN allergy_NN or_CC a_DT history_NN of_IN immediate_JJ and/or_CC anaphylactic_JJ reaction_NN to_TO penicillins_NNS ._SENT In_IN some_DT parts_NNS of_IN the_DT world_NN ,_, azithromycin_NP ,_, a_DT 15-membered_JJ macrolide_NN ,_, is_VBZ used_VBN to_TO treat_VB gonorrhea_NN (_( 1_CD g_NN orally_RB in_IN a_DT single_JJ dose_NN )_) ,_, but_CC this_DT dosage_NN is_VBZ not_RB recommended_VBN for_IN such_JJ use_NN in_IN Canada_NP ._SENT In_IN Canada_NP ,_, azithromycin_NN (_( 1_CD g_NN dose_NN )_) is_VBZ used_VBN either_RB to_TO treat_VB Chlamydia_NP trachomatis_NN infections_NNS or_CC in_IN conjunction_NN with_IN expanded_JJ spectrum_NN cephalosporins_NNS or_CC quinolones_NNS to_TO treat_VB coinfections_NNS of_IN gonococcus_NN and_CC C._NP trachomatis_NN ._SENT The_DT increased_VBN use_NN of_IN azithromycin_NN in_IN treating_VBG other_JJ diseases_NNS may_MD increase_VB the_DT selective_JJ pressure_NN for_IN macrolide-resistant_JJ gonococcus_NN ._SENT Macrolides_NNS such_JJ as_IN erythromycin_NN and_CC azithromycin_NN act_NN by_IN binding_VBG to_TO the_DT 50S_JJ subunit_NN of_IN bacterial_JJ ribosomes_NNS and_CC restrain_VB protein_NN synthesis_NN by_IN inhibiting_VBG the_DT elongation_NN of_IN peptide_NN chains_NNS ._SENT The_DT mechanisms_NNS of_IN resistance_NN to_TO macrolides_NNS include_VBP efflux_NN of_IN these_DT antibiotics_NNS and_CC modification_NN of_IN the_DT ribosomal_JJ target_NN by_IN modification_NN of_IN enzymes_NNS or_CC mutations_NNS to_TO reduce_VB the_DT affinity_NN of_IN the_DT antibiotics_NNS for_IN ribosomes_NNS ._SENT A_DT number_NN of_IN bacterial_JJ efflux_NN systems_NNS which_WDT confer_VBP macrolide_NN resistance_NN have_VBP been_VBN described_VBN ._SENT The_DT first_JJ efflux_NN pump_NN described_VBN for_IN Neisseria_NP gonorrhoeae_NNS was_VBD the_DT MtrC-MtrD-MtrE_NP system_NN ,_, encoded_VBN by_IN the_DT mtrRCDE_JJ operon_NN ,_, which_WDT exports_VBZ hydrophobic_JJ agents_NNS including_VBG dyes_NNS such_JJ as_IN crystal_NN violet_NN and_CC macrolides_NNS such_JJ as_IN azithromycin_NN and_CC erythromycin_NN ._SENT A_DT fourth_JJ Mtr_NP protein_NN (_( MtrF_NP )_) may_MD also_RB be_VB associated_VBN with_IN this_DT efflux_NN system_NN ._SENT The_DT MtrR_NP protein_NN regulates_VBZ the_DT expression_NN of_IN MtrCDE_NN ,_, and_CC increased_VBD expression_NN of_IN the_DT MtrCDE_JJ pump_NN is_VBZ due_JJ to_TO either_CC the_DT lack_NN of_IN the_DT repressor_NN (_( MtrR_NP )_) protein_NN (_( through_IN deletion_NN or_CC insertional_JJ inactivation_NN of_IN mtrR_NP )_) or_CC a_DT mutation_NN of_IN the_DT promoter_NN region_NN of_IN this_DT repressor_NN gene_NN ._SENT More_RBR recently_RB ,_, another_DT macrolide_NN efflux_NN pump_NN ,_, encoded_VBN by_IN the_DT mef_NN gene_NN ,_, which_WDT had_VBD originally_RB been_VBN described_VBN for_IN some_DT of_IN the_DT gram-positive_JJ organisms_NNS ,_, has_VBZ now_RB been_VBN found_VBN in_IN clinical_JJ strains_NNS of_IN N._NP gonorrhoeae_NNS ._SENT Mechanisms_NNS of_IN resistance_NN related_VBN to_TO modification_NN of_IN the_DT ribosomal_JJ target_NN by_IN methylases_NNS have_VBP been_VBN described_VBN for_IN Streptococcus_NP pneumoniae_NNS ,_, Staphylococcus_NP aureus_NN ,_, and_CC N.gonorrhoeae_NP ._SENT There_EX are_VBP reports_NNS of_IN the_DT emergence_NN of_IN azithromycin-resistant_JJ gonococci_NNS which_WDT show_VBP cross-resistance_NN with_IN erythromycin_NN ._SENT One_CD study_NN showed_VBD that_IN strains_NNS from_IN Uruguay_NP and_CC Seattle_NP ,_, Washington_NP ,_, had_VBD acquired_VBN from_IN other_JJ bacterial_JJ species_NNS one_CD or_CC more_JJR of_IN the_DT 23S_JJ rRNA_JJ methylases_NNS [_SYM erm(B)_JJ ,_, erm(C)_NN and_CC erm(F)_NNS ]_SYM which_WDT modified_VBD the_DT antimicrobial_JJ targets_NNS ._SENT Another_DT ribosomal_JJ modification_NN ,_, which_WDT involves_VBZ mutations_NNS in_IN the_DT peptidyltransferase_NN loop_NN in_IN domain_NN V_NN of_IN 23S_JJ rRNA_NN ,_, also_RB confers_VBZ resistance_NN to_TO macrolides_NNS ._SENT This_DT mechanism_NN has_VBZ been_VBN described_VBN in_IN a_DT variety_NN of_IN organisms_NNS :_: Escherichia_NN coli_NNS ,_, Streptococcus_NP pneumoniae_NNS ,_, and_CC Helicobacter_NP pylori_NNS ._SENT Mutants_NNS selected_VBN for_IN resistance_NN to_TO macrolides_NNS have_VBP a_DT substitution_NN at_IN nucleotide_NN position_NN 2058_CD (_( E._NP coli_NNS coordinates_NNS ;_: GenBank_NP accession_NN number_NN )_) or_CC at_IN nearby_JJ nucleotides_NNS ,_, suggesting_VBG their_PP$ involvement_NN in_IN the_DT binding_NN of_IN these_DT macrolides_NNS to_TO domain_NN V_NN of_IN 23S_JJ rRNA_NN ._SENT Point_NN mutations_NNS in_IN ribosomal_JJ proteins_NNS L4_NP (_( rplD_NN )_) and_CC L22_NP (_( rplV_NP )_) conferring_VBG resistance_NN to_TO macrolides_NNS have_VBP been_VBN described_VBN for_IN E._NP coli_NNS ._SENT More_RBR recently_RB ,_, mutations_NNS of_IN ribosomal_JJ protein_NN L4_NP were_VBD also_RB described_VBN for_IN macrolide-resistant_JJ S._NP pneumoniae_NNS ._SENT Proteins_NPS L4_NP and_CC L22_NP primarily_RB bind_VB to_TO domain_NN I_PP of_IN 23S_JJ rRNA_NN ,_, but_CC macrolide_NN resistance_NN mutations_NNS in_IN these_DT proteins_NNS cause_VBP a_DT change_NN in_IN the_DT conformation_NN in_IN domains_NNS II_NP ,_, III_NP ,_, and_CC V_NN affecting_VBG the_DT action_NN of_IN the_DT macrolides_NNS for_IN domain_NN V_NN of_IN 23S_JJ rRNA_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Secondary_JJ structure_NN of_IN the_DT peptidyltransferase_NN loop_NN in_IN domain_NN V_NN of_IN 23S_JJ rRNA_NN ._SENT Secondary_JJ structure_NN of_IN the_DT peptidyltransferase_NN loop_NN in_IN domain_NN V_NN of_IN 23S_JJ rRNA_NN ._SENT Nucleotide_NN numbering_VBG is_VBZ that_IN of_IN E._NP coli_NNS 23S_JJ rRNA_NN ;_: the_DT corresponding_JJ N._NP gonorrhoeae_NNS ,_, S._NP pneumoniae_NNS ,_, and_CC H.pylori_NP numbers_NNS are_VBP in_IN parentheses_NNS ._SENT The_DT C->T_NP mutation_NN at_IN position_NN 2611_CD (_( position_NN 2599_CD in_IN alleles_NNS 1_CD and_CC 2_CD and_CC position_VB 2605_CD in_IN allele_NN 4_CD )_) in_IN N._NP gonorrhoeae_NNS strains_VBZ 20869_CD and_CC 20870_CD ,_, also_RB previously_RB reported_VBN for_IN E._NP coli_NNS ,_, is_VBZ indicated_VBN by_IN a_DT square_NN ._SENT The_DT other_JJ mutations_NNS that_WDT confer_VBP macrolide_NN drug_NN resistance_NN are_VBP circled_VBN :_: G2057_NP (_( E._NP coli_NNS numbering_VBG )_) and_CC G2141_NP (_( H._NP pylori_NNS numbering_VBG )_) ;_: A2058_NP (_( E._NP coli_NNS numbering_VBG )_) ,_, A2142_NP (_( H._NP pylori_NNS numbering_VBG )_) ,_, and_CC A2060_NP (_( S._NP pneumoniae_NP numbering_VBG )_) ;_: A2143_NP (_( H._NP pylori_NNS numbering_VBG )_) ;_: and_CC A2064_NP (_( S._NP pneumoniae_NP numbering_VBG )_) ._SENT In_IN 1997_CD ,_, we_PP detected_VBD in_IN Canada_NP the_DT emergence_NN of_IN azithro-mycin-resistant_JJ N._NP gonorrhoeae_NNS strains_NNS (_( MIC_JJ >=_NN 2.0_CD mug/ml_NN )_) which_WDT also_RB have_VBP resistance_NN to_TO erythromycin_NN (_( MIC_JJ >=_NN 2.0_CD mug/ml_NN )_) ._SENT In_IN this_DT study_NN ,_, we_PP determined_VBD the_DT phenotypic_JJ characteristics_NNS of_IN 56_CD azithromycin-resistant_JJ N._NP gonorrhoeae_NNS strains_NNS which_WDT were_VBD isolated_VBN in_IN Canada_NP between_IN 1997_CD and_CC 1999_CD and_CC investigated_VBD their_PP$ mechanisms_NNS of_IN macrolide_NN resistance_NN ._SENT Bacterial_JJ strains_NNS ._SENT |_SYM Between_IN 1997_CD and_CC 1999_CD ,_, a_DT total_NN of_IN 56_CD erythromycin-_NN and_CC azithromycin-resistant_JJ N._NP gonorrhoeae_NNS isolates_NNS were_VBD collected_VBN as_IN part_NN of_IN the_DT National_NP Surveillance_NP of_IN N._NP gonorrhoeae_NNS Program_NN in_IN Canada_NP ._SENT The_DT strains_NNS used_VBN in_IN this_DT study_NN originated_VBN from_IN British_NP Columbia_NP ,_, Alberta_NP ,_, Ontario_NP ,_, Quebec_NP ,_, and_CC Nova_NP Scotia_NP ._SENT N._NP gonorrhoeae_NNS strains_NNS were_VBD subcultured_VBN on_IN GC_NP medium_NN base_NN (_( GCMB_NP )_) (_( Difco_NP Laboratories_NP ,_, Detroit_NP ,_, Mich._NP )_) containing_VBG 0.2_CD %_NN BioX_NP (_( QueLab_NP ,_, Montreal_NP ,_, Quebec_NP ,_, Canada_NP )_) and_CC incubated_VBN for_IN 24_CD h_NN at_IN 35C_JJ in_IN a_DT 5_CD %_NN CO2_JJ atmosphere_NN with_IN or_CC without_IN antibiotics_NNS and_CC maintained_VBN in_IN brain_NN heart_NN infusion_NN (_( BHI_NP )_) medium_NN (_( Difco_NP Laboratories_NPS )_) containing_VBG 20_CD %_NN glycerol_NN and_CC stored_VBD at_IN -80C_NN ._SENT All_DT other_JJ nonfastidious_JJ organisms_NNS were_VBD grown_VBN aerobically_RB on_IN BHI_NP medium_NN ._SENT Antimicrobial_JJ susceptibility_NN testing_NN and_CC strain_NN characterization_NN ._SENT |_SYM Antimicrobial_JJ susceptibilities_NNS of_IN N._NP gonorrhoeae_NNS to_TO azithromycin_NNS (_( compliments_NNS of_IN Pfizer_NP ,_, Pointe-Claire/Dorval_NP ,_, Quebec_NP ,_, Canada_NP )_) ,_, cefixime_NN (_( Wyeth-Ayerst_NP Laboratories_NP ,_, Mason_NP ,_, Mich._NP )_) ,_, ceftriaxone_NP (_( Roche_NP ,_, Laval_NP ,_, Quebec_NP ,_, Canada_NP )_) ,_, ciprofloxacin_NN (_( compliments_NNS of_IN Bayer_NP ,_, Etobicoke_NP ,_, Ontario_NP ,_, Canada_NP )_) ,_, erythromycin_NN (_( compliments_NNS of_IN Lilly_NP ,_, Indianapolis_NP ,_, Ind._NP )_) ,_, penicillin_NN (_( compliments_NNS of_IN Novopharm_NP ,_, Scarborough_NP ,_, Ontario_NP )_) ,_, spectinomycin_NN (_( compliments_NNS of_IN Pharmacia_NP &_CC Upjohn_NP ,_, Kalamazoo_NP ,_, Mich._NP )_) ,_, and_CC tetracycline_NN (_( Sigma-Aldrich_NP Canada_NP Ltd._NP ,_, Oakville_NP )_) were_VBD performed_VBN according_VBG to_TO the_DT agar_NN dilution_NN method_NN described_VBN by_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NP (_( NCCLS_NP )_) ,_, but_CC the_DT GC_NP medium_NN base_NN was_VBD modified_VBN to_TO contain_VB 1_CD %_NN Kellogg_NN 's_POS supplement_NN (_( 0.05_CD g_NN of_IN ferric_JJ nitrate_NN ,_, 1.0_CD g_NN of_IN cocarboxylase_NN ,_, 5.0_CD g_NN of_IN glutamine_NN ,_, 200.0_CD g_NN of_IN glucose_NN in_IN 1_CD liter_NN of_IN H2O_NP )_) ._SENT The_DT MICs_NP of_IN all_DT antibiotics_NNS except_IN azithromycin_NN and_CC erythromycin_NN (_( for_IN which_WDT there_EX are_VBP no_DT NCCLS_NP MIC_NP breakpoints_NNS )_) were_VBD interpreted_VBN according_VBG to_TO the_DT NCCLS_NP guidelines_NNS ._SENT For_IN the_DT purposes_NNS of_IN this_DT study_NN ,_, the_DT azithromycin_NN and_CC erythromycin_NN MICs_NNS at_IN which_WDT strains_NNS exhibited_VBD resistance_NN were_VBD defined_VBN as_IN >=2.0_JJ mug/ml_NN ._SENT N._NP gonorrhoeae_NNS reference_NN cultures_NNS ATCC_NP 49226_CD ,_, WHO_WP III_NP ,_, WHO_WP V_NN ,_, and_CC WHO_WP VII_NP were_VBD used_VBN as_IN quality_NN control_NN strains_NNS ._SENT Susceptibility_NN to_TO crystal_NN violet_NN was_VBD used_VBN as_IN an_DT indicator_NN of_IN efflux_NN ,_, and_CC crystal_NN violet_NN susceptibility_NN assays_NNS were_VBD performed_VBN as_IN previously_RB described_VBN ._SENT Auxotyping_VBG of_IN the_DT N._NP gonorrhoeae_NN strains_NNS was_VBD performed_VBN as_IN previously_RB described_VBN on_IN a_DT chemically_RB defined_VBN medium_NN to_TO determine_VB their_PP$ nutritional_JJ requirements_NNS for_IN leucine_NN (_( L_NP )_) ,_, ornithine_NN (_( O_NP )_) ,_, citrulline_NN (_( C_NP )_) ,_, proline_NN (_( P_NN )_) ,_, arginine_NN (_( A_NP )_) ,_, hypoxanthine_NN (_( H_NP )_) ,_, uracil_NN (_( U_NP )_) ,_, and_CC methionine_NN (_( M_NP )_) ._SENT Prototype_NN strains_NNS that_WDT did_VBD not_RB require_VB amino_NN acid_NN supplements_NNS for_IN growth_NN were_VBD designated_VBN NR_NP (_( no_DT requirements_NNS )_) ._SENT Serotyping_VBG of_IN the_DT N._NP gonorrhoeae_NN isolates_NNS was_VBD performed_VBN as_IN described_VBN by_IN Knapp_NP et_FW al._FW ._SENT Plasmid_NP profiles_NNS of_IN the_DT N._NP gonorrhoeae_NN isolates_NNS were_VBD performed_VBN as_IN previously_RB described_VBN ._SENT PCR_NP and_CC DNA_NP sequencing_NP of_IN the_DT macrolide_NN resistance_NN targets_NNS ._SENT |_SYM PCR_NP was_VBD used_VBN to_TO determine_VB the_DT presence_NN or_CC absence_NN of_IN methylase_NN genes_NNS and_CC to_TO determine_VB mutations_NNS in_IN the_DT mtr_NN efflux_NN pump_NN and_CC ribosomal_JJ genes_NNS ._SENT Using_VBG PCR_NP with_IN primers_NNS and_CC conditions_NNS as_IN previously_RB described_VBN ,_, clinical_JJ isolates_NNS were_VBD tested_VBN for_IN the_DT presence_NN of_IN one_CD or_CC more_JJR of_IN the_DT methylase_NN genes_NNS encoded_VBN by_IN erm(A)_NN ,_, erm(B)_NN ,_, erm(C)_NN ,_, erm(F)_NN ,_, and_CC an_DT efflux_NN pump_NN mef(A)_NN ._SENT The_DT following_VBG reference_NN strains_NNS were_VBD used_VBN as_IN positive_JJ controls_NNS for_IN PCR_NP :_: for_IN erm(A)_NN ,_, Staphylococcus_NP aureus_NN RN1389_NP ;_: for_IN erm(B)_NN ,_, Streptococcus_NP pyogenes_NNS AC1_JJ ;_: for_IN erm(C)_NN ,_, S._NP aureus_NN RN4220_NP ;_: for_IN erm(F)_NN ,_, E._NP coli_NNS V831_JJ ;_: and_CC for_IN mef(A)_NN ,_, S._NP pyogenes_NNS 02C1064_NN ._SENT In_IN an_DT attempt_NN to_TO identify_VB point_NN mutations_NNS ,_, sequences_NNS of_IN genes_NNS related_VBN to_TO macrolide_NN resistance_NN were_VBD determined_VBN for_IN the_DT mtrR_NP promoter_NN region_NN ,_, domain_NN V_NN of_IN the_DT 23S_JJ rRNA_NN ,_, and_CC rplD_NN and_CC rplV_NN (_( encoding_VBG ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP ,_, respectively_RB )_) ._SENT The_DT mtrR_NP promoter_NN region_NN of_IN the_DT mtrR_NP efflux_NN pump_NN operon_NN was_VBD amplified_VBN using_VBG the_DT published_VBN primers_NNS RPMAL#2_JJ (_( 5_CD '_POS -ACTGAAGCTTATTTCCGGCGCAGGCAGGG-3_NN '_'' )_) and_CC KH9#3_NP (_( 5'-GACGACAGTGCCAATGCAACG-3_NP '_POS )_) and_CC sequenced_JJ in_IN an_DT attempt_NN to_TO identify_VB mutations_NNS in_IN this_DT region_NN ._SENT To_TO identify_VB mutations_NNS within_IN domain_NN V_NN (_( of_IN the_DT peptidyltransferase_NN loop_NN )_) for_IN each_DT of_IN the_DT four_CD copies_NNS of_IN the_DT 23S_JJ rRNA_NN gene_NN ,_, a_DT two-step_JJ PCR_NP method_NN was_VBD developed_VBN ._SENT The_DT first_JJ step_NN used_VBD the_DT gonrRNA-F_NN primer_NN ,_, paired_VBN with_IN a_DT specific_JJ primer_NN for_IN each_DT of_IN the_DT 23S_JJ rRNA_NN alleles_NNS listed_VBN in_IN Table_NP ,_, to_TO amplify_VB specific_JJ regions_NNS of_IN 23S_JJ rRNA_NN in_IN eight_CD strains_NNS ._SENT PCR_NP conditions_NNS were_VBD 1_CD min_NN of_IN denaturation_NN at_IN 94C_NN ,_, 1.5_CD min_NN at_IN 66C_JJ (_( for_IN alleles_NNS 2_CD and_CC 3_CD of_IN domain_NN V_CD )_) or_CC 68C_JJ (_( for_IN alleles_NNS 1_CD and_CC 4_CD of_IN domain_NN V_CD )_) for_IN annealing_VBG ,_, and_CC 2.5_CD min_NN at_IN 72C_NP for_IN elongation_NN for_IN 30_CD cycles_NNS ._SENT The_DT amplicons_NNS obtained_VBN were_VBD then_RB used_VBN as_IN templates_NNS in_IN a_DT second_JJ PCR_NP using_VBG gonrRNA-F_NN and_CC gonrRNA-R2_JJ primers_NNS to_TO amplify_VB the_DT peptidyltransferase_NN loop_NN for_IN sequencing_VBG determination_NN ._SENT The_DT conditions_NNS for_IN this_DT PCR_NP step_NN were_VBD 94C_NN at_IN 1_CD min_NN for_IN denaturing_VBG ,_, 59C_NN for_IN 1_CD min_NN for_IN annealing_VBG ,_, and_CC 72C_NP at_IN 1_CD min_NN for_IN elongation_NN for_IN 35_CD cycles_NNS ._SENT PCR_NP products_NNS were_VBD also_RB sequenced_JJ in_IN an_DT attempt_NN to_TO identify_VB point_NN mutations_NNS in_IN rplD_NN and_CC rplV_NN genes_NNS in_IN ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP ,_, respectively_RB ._SENT All_DT PCR_NP amplicons_NNS were_VBD purified_VBN (_( Promega_NP PCR_NP Prep_NP Kit_NP ;_: Fisher_NP ,_, Nepean_NP ,_, Ontario_NP ,_, Canada_NP )_) ,_, and_CC both_DT strands_NNS were_VBD sequenced_VBN using_VBG an_DT ABI_NP Prism_NN 377_CD DNA_NN sequencing_VBG system_NN (_( Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) ._SENT DNA_NP sequences_NNS were_VBD aligned_VBN using_VBG BLAST_NP and_CC GenBank_NP programs_NNS to_TO identify_VB the_DT mutations_NNS of_IN these_DT genes_NNS ._SENT Transformation_NN studies_NNS ._SENT |_SYM Total_JJ genomic_JJ DNA_NN from_IN both_DT clinical_JJ strain_NN 20870_CD and_CC strain_VB 19416_CD was_VBD introduced_VBN into_IN piliated_JJ N._NP gonorrhoeae_NN F62_NP (_( MICs_NP of_IN erythromycin_NN and_CC azithromycin_NN ,_, 0.25_CD and_CC 0.125_CD mug/ml_NN ,_, respectively_RB )_) by_IN transformation_NN ._SENT As_IN a_DT control_NN ,_, a_DT ciprofloxacin-resistant_JJ strain_NN with_IN a_DT ciprofloxacin_NN MIC_NN of_IN 8.0_CD mug/ml_NN and_CC with_IN identified_VBN mutations_NNS of_IN gyrA_NN and_CC parC_NN was_VBD transformed_VBN into_IN F62_NP ._SENT Briefly_RB ,_, N._NP gonorrhoeae_NNS F62_NP was_VBD suspended_VBN in_IN 1_CD ml_NN of_IN 10_CD mM_NP Tris-HCl-10_NP mM_NP EDTA_NP disodium_NN salt_NN (_( pH_NN 8.0_CD )_) to_TO an_DT optical_JJ density_NN of_IN 0.60_CD to_TO 0.63_CD at_IN 600_CD nm_NN ,_, inoculated_VBN on_IN GCMB_NP ,_, and_CC incubated_VBD for_IN 1_CD h_NN at_IN 37C_JJ in_IN an_DT atmosphere_NN enriched_VBN with_IN 7_CD %_NN CO2_NN ._SENT Chromosomal_JJ or_CC amplified_VBN DNA_NN (_( 1_CD mug_NN )_) was_VBD then_RB applied_VBN to_TO the_DT inoculated_VBN plate_NN ._SENT After_IN a_DT 24-h_JJ incubation_NN period_NN ,_, individual_JJ colonies_NNS from_IN the_DT GCMB_NP plates_NNS were_VBD transferred_VBN to_TO GCMB_NP containing_VBG erythromycin_NN (_( 0.5_CD ,_, 1.0_CD ,_, and_CC 2.0_CD mug/ml_NN )_) ._SENT Potential_JJ transformants_NNS were_VBD again_RB subcultured_VBN onto_IN GCMB_NP containing_VBG erythromycin_NN (_( 0.5_CD ,_, 1.0_CD ,_, and_CC 2.0_CD mug/ml_NN )_) prior_RB to_TO MIC_JJ determination_NN and_CC examination_NN of_IN mutations_NNS in_IN the_DT 23S_JJ rRNA_NN and_CC the_DT promoter_NN region_NN of_IN mtrR_NP ._SENT In_IN vitro_NN conversion_NN of_IN resistant_JJ strains_NNS to_TO susceptibility_NN ._SENT |_SYM The_DT following_VBG procedure_NN was_VBD performed_VBN to_TO obtain_VB spontaneous_JJ susceptible_JJ revertants_NNS from_IN macrolide-resistant_JJ strains_NNS ._SENT Single_JJ colonies_NNS of_IN the_DT macrolide-resistant_NN cultures_VBZ 20869_CD and_CC 20870_CD (_( erythromycin_NN MIC_NP ,_, 64.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 4.0_CD mug/ml_NN )_) were_VBD subcultured_VBN daily_RB for_IN 7_CD days_NNS onto_IN nonselective_JJ GCMB_NP plates_NNS ._SENT Fifty_CD isolated_JJ colonies_NNS were_VBD randomly_RB selected_VBN and_CC replicated_VBN onto_IN GCMB_NP plates_NNS with_IN and_CC without_IN erythromycin_NN (_( 8.0_CD mug/ml_NN )_) ,_, and_CC another_DT single_JJ colony_NN was_VBD also_RB subcultured_VBN onto_IN GCMB_NP to_TO obtain_VB isolated_JJ colonies_NNS ._SENT This_DT step_NN was_VBD repeated_VBN until_IN colonies_NNS on_IN replicated_VBN plates_NNS grew_VBD on_IN GCMB_NP but_CC not_RB on_IN erythromycin_NN plates_NNS (_( 8.0_CD mug/ml_NN )_) after_IN 3_CD days_NNS of_IN culturing_VBG ._SENT Mutants_NNS with_IN decreased_VBN susceptibility_NN were_VBD selected_VBN for_IN MIC_JJ determination_NN ._SENT Sequencing_VBG of_IN the_DT mtrR_NP promoter_NN region_NN flanking_VBG mtrC_NP and_CC mtrR_NP and_CC the_DT domain_NN V_CD region_NN of_IN the_DT four_CD alleles_NNS of_IN 23S_JJ rRNA_NN (_( rrl_NN gene_NN )_) of_IN the_DT resistant_JJ mutants_NNS and_CC of_IN the_DT susceptible_JJ parent_NN strains_NNS was_VBD also_RB performed_VBN ,_, and_CC the_DT results_NNS were_VBD compared_VBN ._SENT In_IN vitro_NN mutation_NN to_TO erythromycin_NN resistance_NN ._SENT |_SYM To_TO generate_VB macrolide-resistant_JJ mutants_NNS ,_, the_DT following_VBG procedure_NN was_VBD performed_VBN ._SENT Three_CD susceptible_JJ N._NP gonorrhoeae_NNS strains_NNS (_( 21855_CD ,_, 21305_CD ,_, and_CC 22831_LS )_) (_( erythromycin_NN and_CC azithromycin_NN MICs_NNS ,_, 0.5_CD to_TO 1_CD and_CC 0.125_CD ,_, respectively_RB )_) were_VBD selected_VBN from_IN our_PP$ culture_NN collection_NN and_CC subcultured_VBN onto_IN nonselective_JJ GCMB_NP plates_NNS ._SENT After_IN a_DT 24-h_JJ incubation_NN period_NN ,_, the_DT growth_NN from_IN a_DT single_JJ colony_NN of_IN each_DT strain_NN was_VBD swabbed_VBN onto_IN the_DT entire_JJ surface_NN of_IN GCMB_NP plates_NNS containing_VBG a_DT gradient_NN of_IN erythromycin_NN of_IN 0_CD to_TO 4.0_CD mug/ml_NN ._SENT After_IN a_DT 24-h_JJ incubation_NN ,_, the_DT plates_NNS were_VBD examined_VBN for_IN growth_NN and_CC isolated_JJ colonies_NNS on_IN the_DT highest_JJS concentration_NN of_IN antibiotics_NNS were_VBD selected_VBN and_CC streaked_VBN onto_IN another_DT GCMB_NP gradient_JJ plate_NN with_IN a_DT concentration_NN of_IN erythromycin_NN from_IN 0_CD to_TO 4.0_CD mug/ml_NN ._SENT After_IN the_DT selection_NN step_NN was_VBD repeated_VBN seven_CD times_NNS ,_, a_DT gradient_JJ plate_NN with_IN a_DT higher_JJR concentration_NN of_IN erythromycin_NN (_( 0_CD to_TO 12.0_CD mug/ml_NN )_) was_VBD used_VBN ._SENT Colonies_NNS in_IN the_DT region_NN of_IN the_DT highest_JJS concentration_NN of_IN erythromycin_NN were_VBD selected_VBN and_CC subcultured_VBN onto_IN three_CD plates_NNS ,_, namely_RB ,_, a_DT GCMB_NP gradient_JJ plate_NN (_( 0_CD to_TO 12.0_CD mug_NN of_IN erythromycin/ml_NN )_) ,_, a_DT GMCB_NP plate_NN containing_VBG erythromycin_NN at_IN 8.0_CD mug/ml_NN ,_, and_CC a_DT GCMB_NP plate_NN containing_VBG erythromycin_NN at_IN 16.0_CD mug/ml_NN ._SENT Colonies_NNS that_WDT grew_VBD on_IN GCMB_NP containing_VBG erythromycin_NN (_( 8.0_CD or_CC 16.0_CD mug/ml_NN )_) were_VBD subcultured_VBN twice_RB prior_RB to_TO MIC_JJ determination_NN ._SENT Sequencing_VBG of_IN the_DT mtrR_NP promoter_NN region_NN between_IN mtrC_NP and_CC mtrR_NP and_CC the_DT domain_NN V_CD region_NN of_IN the_DT four_CD alleles_NNS of_IN 23S_JJ rRNA_NN (_( rrl_NN gene_NN )_) of_IN the_DT resistant_JJ mutants_NNS and_CC of_IN the_DT susceptible_JJ parent_NN strains_NNS was_VBD also_RB performed_VBN ,_, and_CC the_DT resulting_VBG sequences_NNS were_VBD compared_VBN ._SENT Nucleotide_NN sequence_NN accession_NN numbers_NNS ._SENT |_SYM The_DT nucleotide_NN sequences_NNS of_IN the_DT four_CD alleles_NNS of_IN 23S_JJ rRNA_NN for_IN strains_NNS 20869_CD and_CC 20870_CD have_VBP been_VBN deposited_VBN in_IN GenBank_NP under_IN accession_NN numbers_NNS to_TO ._SENT TABLE_NN 1_CD |_SYM Oligonucleotides_NP used_VBN in_IN the_DT amplification_NN of_IN the_DT four_CD alleles_NNS of_IN the_DT peptidyltransferase_NN region_NN in_IN domain_NN V_NN of_IN the_DT 23S_JJ rRNA_NN Antibiotic_JJ susceptibilities_NNS and_CC characterization_NN of_IN N._NP gonorrhoeae_NNS isolates_NNS ._SENT |_SYM Our_NN laboratory_NN began_VBD monitoring_VBG azithromycin_NN resistance_NN in_IN 1996_CD ,_, and_CC the_DT emergence_NN of_IN resistant_JJ strains_NNS was_VBD first_RB observed_VBN in_IN 1997_CD in_IN Canada_NP ._SENT During_IN 1997_CD to_TO 1999_CD ,_, 56_CD azithromycin-resistant_JJ N._NP gonorrhoeae_NNS strains_NNS (_( MICs_NP ,_, 2.0_CD to_TO 4.0_CD mug/ml_NN )_) were_VBD isolated_VBN in_IN five_CD provinces_NNS in_IN Canada_NP (_( Quebec_NP ,_, British_NP Columbia_NP ,_, Ontario_NP ,_, Alberta_NP ,_, and_CC Nova_NP Scotia_NP )_) ._SENT In_IN 1997_CD ,_, 95_CD %_NN (_( 19_CD of_IN 20_CD )_) of_IN the_DT azithromycin-resistant_JJ strains_NNS were_VBD isolated_VBN from_IN Quebec_NP and_CC only_RB 1_CD other_JJ strain_NN was_VBD isolated_VBN from_IN British_NP Columbia_NP ._SENT In_IN 1998_CD ,_, 52_CD %_NN (_( 13_CD of_IN 25_CD )_) of_IN the_DT azithromycin-resistant_JJ strains_NNS were_VBD from_IN British_NP Columbia_NP ,_, 5_CD from_IN Ontario_NP ,_, 3_CD from_IN Alberta_NP ,_, 2_CD from_IN Nova_NP Scotia_NP ,_, and_CC 2_CD from_IN Quebec_NP ._SENT Of_IN the_DT 11_CD strains_NNS isolated_VBN in_IN 1999_CD ,_, 8_CD were_VBD from_IN British_NP Columbia_NP and_CC 3_CD were_VBD from_IN Quebec_NP ._SENT The_DT 56_CD strains_NNS were_VBD classified_VBN into_IN 16_CD types_NNS by_IN auxotype_NN and_CC serotype_NN (_( A/S_NP )_) ._SENT The_DT most_RBS common_JJ classes_NNS were_VBD type_NN NR/IB-01_NN (_( 33_CD strains_NNS [_SYM 58.9_CD %_NN ]_SYM )_) and_CC type_NN NR/IB-03_NN (_( 6_CD strains_NNS [_SYM 10.7_CD %_NN ]_SYM )_) ._SENT Three_CD A/S_NP classes_NNS had_VBD two_CD strains_NNS each_DT ,_, NR/IA-04_NP ,_, H/IB-01_NP ,_, and_CC H/IB-03_NP ._SENT Eleven_NN A/S_NP classes_NNS (_( NR/IB-06_NP ,_, NR/IB-10_NP ,_, NR/IB-14_NP ,_, NR/IB-17_NP ,_, NR/IB-23_NP ,_, NR/IB-32_NP ,_, NR/IB-26_NP ,_, H/IB-20_NP ,_, P/IB-03_NP ,_, P/IB-02_NP ,_, and_CC P/serotype_NP [_SYM not_RB typeable_NN ]_SYM )_) each_DT had_VBD a_DT unique_JJ strain_NN ._SENT All_PDT the_DT strains_NNS contained_VBD a_DT 2.6-mDa_JJ plasmid_NN ,_, except_IN for_IN one_CD P-requiring_NN strain_NN ._SENT All_DT azithromycin-resistant_JJ strains_NNS (_( azithromycin_NP MIC_NP >=_NN 2.0_CD mug/ml_NN )_) were_VBD also_RB resistant_JJ to_TO erythromycin_NN (_( erythromycin_NN MIC_NN >=_NN 2.0_CD mug/ml_NN )_) ._SENT Some_DT of_IN these_DT strains_NNS (_( 58.9_CD %_NN )_) also_RB had_VBD chromosome-mediated_JJ resistance_NN to_TO both_DT tetracycline_NN and_CC penicillin_NN ,_, and_CC the_DT remaining_VBG 41.1_CD %_NN were_VBD resistant_JJ to_TO tetracycline_NN (_( tetracycline_NN MIC_NN >=_NN 2.0_CD mug/ml_NN )_) ._SENT A_DT total_NN of_IN 96.4_CD %_NN of_IN the_DT azithromycin-resistant_JJ strains_NNS showed_VBD resistance_NN to_TO crystal_NN violet_NN (_( crystal_NN violet_NN MICs_NNS >=_JJ 1.0_CD mug/ml_NN )_) ,_, indicating_VBG that_IN their_PP$ cell_NN envelopes_NNS may_MD have_VB had_VBD reduced_VBN permeability_NN ._SENT Detection_NN of_IN mechanisms_NNS of_IN macrolide_NN resistance_NN ._SENT |_SYM Several_JJ targets_NNS were_VBD used_VBN to_TO determine_VB different_JJ mechanisms_NNS of_IN resistance_NN in_IN the_DT azithromycin-resistant_JJ N._NP gonorrhoeae_NNS ._SENT Forty-six_NP selected_VBD strains_NNS ,_, including_VBG strains_NNS from_IN all_DT A/S_NP classes_NNS and_CC strains_NNS from_IN different_JJ geographical_JJ locations_NNS ,_, were_VBD all_RB negative_JJ by_IN PCR_NP for_IN rRNA_NN methylases_NNS using_VBG erm(A)_NN ,_, erm(B)_NN ,_, erm(C)_NN ,_, or_CC erm(F)_JJ (_( data_NNS not_RB shown_VBN )_) ,_, indicating_VBG that_IN our_PP$ azithromycin-resistant_JJ strains_NNS did_VBD not_RB have_VB the_DT same_JJ mechanisms_NNS of_IN macrolide_NN resistance_NN as_IN those_DT found_VBN in_IN Seattle_NP and_CC Uruguay_NP ._SENT PCR_NP amplification_NN of_IN a_DT subset_NN of_IN 14_CD strains_NNS selected_VBN randomly_RB also_RB did_VBD not_RB show_VB the_DT presence_NN of_IN the_DT mef(A)_JJ gene_NN ,_, a_DT macrolide_NN transporter_NN (_( data_NNS not_RB shown_VBN )_) ._SENT PCRs_NNS using_VBG genomic_JJ DNA_NN of_IN control_NN strains_NNS all_RB showed_VBD positive_JJ results_NNS ,_, as_RB expected_VBN ._SENT In_IN addition_NN ,_, the_DT structural_JJ genes_NNS rplD_NN (_( ribosomal_JJ protein_NN L4_NP )_) and_CC rplV_NP (_( ribosomal_JJ protein_NN L22_NP )_) were_VBD examined_VBN for_IN point_NN mutations_NNS ,_, using_VBG nine_CD and_CC eight_CD strains_NNS ,_, respectively_RB ._SENT The_DT DNA_NN sequences_NNS of_IN the_DT rplD_NN and_CC rplV_NN genes_NNS were_VBD similar_JJ to_TO those_DT determined_VBN in_IN a_DT susceptible_JJ N._NP gonorrhoeae_NNS strain_NN ,_, FA1090_NP (_( Gonococcal_NP Genome_NP Sequencing_NP Project_NP ,_, University_NP of_IN Oklahoma_NP )_) ._SENT We_PP concluded_VBD that_IN macrolide_NN resistance_NN in_IN these_DT strains_NNS was_VBD not_RB due_JJ to_TO mutations_NNS of_IN rplD_NN or_CC rplV_NN or_CC to_TO the_DT acquisition_NN of_IN erm_NN genes_NNS ._SENT It_PP has_VBZ been_VBN well_RB established_VBN that_DT overexpression_NN of_IN the_DT mtr_NN efflux_NN pump_NN can_MD play_VB a_DT role_NN in_IN increasing_VBG resistance_NN to_TO macrolides_NNS ._SENT DNA_NP sequencing_NP of_IN the_DT mtrR_NP promoter_NN region_NN in_IN the_DT 14_CD azithromycin-_NN and_CC erythromycin-resistant_NN strains_NNS revealed_VBD that_IN 12_CD of_IN these_DT strains_NNS had_VBD a_DT single-base-pair_JJ deletion_NN within_IN a_DT 13-bp_JJ inverted_JJ repeat_NN within_IN the_DT mtrR_NP promoter_NN ._SENT The_DT deletion_NN which_WDT activates_VBZ the_DT overexpression_NN of_IN the_DT mtr_NN pump_NN in_IN these_DT 12_CD strains_NNS was_VBD the_DT same_JJ mutation_NN as_IN that_WDT reported_VBD for_IN azithromycin-resistant_JJ N._NP gonorrhoeae_NNS strains_NNS in_IN another_DT study_NN ._SENT The_DT other_JJ two_CD azithromycin-resistant_JJ strains_NNS (_( 20869_CD and_CC 20870_CD )_) that_WDT did_VBD not_RB have_VB a_DT mutation_NN in_IN the_DT mtr_NN promoter_NN region_NN therefore_RB have_VBP other_JJ resistance_NN mechanisms_NNS not_RB previously_RB described_VBN for_IN N._NP gonorrhoeae_NNS ._SENT There_EX are_VBP other_JJ mechanisms_NNS of_IN macrolide_NN resistance_NN ,_, including_VBG mutations_NNS in_IN the_DT 23S_JJ rRNA_NN as_IN found_VBN in_IN other_JJ bacteria_NNS ._SENT Therefore_RB ,_, we_PP explored_VBD the_DT possibility_NN that_IN changes_NNS occur_VBP in_IN the_DT 23S_JJ rRNA_NN DNA_NN sequence_NN in_IN strains_NNS 20869_CD and_CC 20870_CD that_WDT affect_VBP their_PP$ susceptibility_NN to_TO macrolides_NNS ._SENT The_DT four_CD copies_NNS of_IN the_DT 23S_JJ rRNA_NN rrl_NN gene_NN present_NN in_IN N._NP gonorrhoeae_NNS were_VBD amplified_VBN individually_RB for_IN domain_NN V_NN in_IN 14_CD azithromycin-resistant_JJ strains_NNS ._SENT Twelve_CD of_IN these_DT strains_NNS did_VBD not_RB have_VB mutations_NNS in_IN the_DT DNA_NP sequence_NN of_IN the_DT 23S_JJ rRNA_NN peptidyltransferase_NN region_NN ._SENT These_DT 12_CD strains_NNS did_VBD have_VB the_DT deletion_NN in_IN the_DT mtr_NN promoter_NN region_NN ._SENT In_IN the_DT remaining_VBG two_CD strains_NNS ,_, 20869_CD and_CC 20870_CD (_( erythromycin_NN MIC_NP ,_, 64.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 4.0_CD mug/ml_NN )_) ,_, alleles_NNS 1_CD ,_, 2_CD ,_, and_CC 4_CD were_VBD found_VBN to_TO contain_VB a_DT C2611T_NP (_( E._NP coli_NNS numbering_VBG )_) mutation_NN ._SENT These_DT mutations_NNS correspond_VBP to_TO position_VB C2599T_NP for_IN alleles_NNS 1_CD and_CC 2_CD and_CC position_NN C2605T_NN for_IN allele_NN 4_CD (_( N._NP gonorrhoeae_NNS numbering_VBG )_) ._SENT Allele_NN 4_CD was_VBD found_VBN to_TO contain_VB base_NN insertions_NNS throughout_IN domain_NN V_NN which_WDT account_VBP for_IN the_DT change_NN in_IN nucleotide_NN position_NN number_NN ._SENT We_PP believe_VBP that_IN this_DT mutation_NN is_VBZ responsible_JJ for_IN macrolide_NN resistance_NN in_IN these_DT two_CD strains_NNS ._SENT The_DT secondary_JJ structure_NN of_IN domain_NN V_NN of_IN the_DT 23S_JJ rRNA_NN gene_NN shown_VBN in_IN Fig._NN ,_, based_VBN on_IN an_DT illustration_NN by_IN Depardieu_NP and_CC Courvalin_NP ,_, revealed_VBD a_DT number_NN of_IN point_NN mutations_NNS previously_RB identified_VBN in_IN other_JJ strains_NNS which_WDT confer_VBP resistance_NN to_TO macrolides_NNS ._SENT These_DT include_VBP the_DT following_VBG positions_NNS and_CC mutations_NNS :_: positions_NNS A2058_NP and_CC A2062_NP (_( E._NP coli_NNS numbering_VBG )_) in_IN S._NP pneumoniae_NNS ;_: positions_NNS G2057_JJ ,_, A2058_NP ,_, and_CC A2059_NP (_( E._NP coli_NNS numbering_VBG )_) in_IN H._NP pylori_NNS ;_: and_CC positions_NNS G2057_JJ ,_, A2058_NP ,_, and_CC C2611_NP in_IN E._NP coli_NNS ._SENT These_DT mutations_NNS most_RBS likely_RB affect_VB the_DT secondary_JJ structure_NN of_IN the_DT peptidyltransferase_NN loop_NN in_IN domain_NN V_NN ,_, due_JJ to_TO the_DT pairing_VBG of_IN different_JJ nucleotides_NNS ._SENT In_IN the_DT N._NP gonorrhoeae_NN strains_VBZ 20869_CD and_CC 20870_CD ,_, the_DT C->T_NP mutation_NN is_VBZ located_VBN in_IN this_DT same_JJ region_NN ._SENT Further_JJR investigation_NN of_IN strains_NNS 20869_CD and_CC 20870_CD revealed_VBD that_IN they_PP did_VBD not_RB have_VB the_DT mutation_NN in_IN the_DT mtrR_NP promoter_NN region_NN causing_VBG the_DT mtrR_NP overexpression_NN nor_CC did_VBD they_PP have_VBP mutations_NNS in_IN the_DT ribosomal_JJ protein_NN L4_NP or_CC L22_NP ._SENT No_DT mutations_NNS were_VBD observed_VBN in_IN allele_NN 3_CD of_IN these_DT two_CD strains_NNS ._SENT Transformation_NN studies_NNS ._SENT |_SYM Transformation_NN studies_NNS were_VBD used_VBN to_TO confirm_VB that_IN mutations_NNS in_IN the_DT rrl_NN gene_NN within_IN the_DT peptidyltransferase_NN loop_NN of_IN domain_NN V_NN of_IN the_DT 23S_JJ rRNA_NN caused_VBD resistance_NN to_TO macrolides_NNS in_IN N._NP gonorrhoeae_NNS ._SENT Transformation_NN of_IN total_JJ genomic_JJ DNA_NN from_IN macrolide-resistant_JJ strain_NN 19416_CD (_( erythromycin_NN MIC_NP ,_, 8.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 2.0_CD mug/ml_NN )_) to_TO N._NP gonorrhoeae_NNS F62_NN (_( an_DT erythromycin-_NN and_CC azithromycin-susceptible_JJ strain_NN )_) yielded_VBD transformants_NNS for_IN which_WDT macrolide_NN MICs_NNS were_VBD increased_VBN (_( erythromycin_NN MIC_NN of_IN 4.0_CD mug/ml_NN )_) ._SENT Sequencing_VBG of_IN the_DT mtrR_NP promoter_NN region_NN revealed_VBD that_IN the_DT transformants_NNS had_VBD the_DT same_JJ deletion_NN (_( A_NP )_) in_IN mtr_NN found_VBN in_IN the_DT donor_NN strain_NN and_CC did_VBD not_RB have_VB mutations_NNS in_IN 23S_JJ rRNA_NN ._SENT Transformation_NN of_IN total_JJ genomic_JJ DNA_NN from_IN macrolide-resistant_JJ strain_NN 20870_CD (_( erythromycin_NN MIC_NP ,_, 64.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 4.0_CD mug/ml_NN )_) to_TO F62_NP yielded_VBD resistant_JJ transformants_NNS (_( erythromycin_NN MIC_NP ,_, 4.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 2.0_CD mug/ml_NN )_) ._SENT However_RB ,_, when_WRB the_DT regions_NNS encoding_VBG domain_NN V_NN of_IN the_DT 4_CD alleles_NNS of_IN the_DT 23S_JJ rRNA_NN rrl_NN gene_NN in_IN the_DT transformants_NNS were_VBD amplified_VBN ,_, their_PP$ DNA_NN sequences_NNS showed_VBD that_IN these_DT strains_NNS did_VBD not_RB have_VB mutations_NNS in_IN the_DT 23S_JJ rRNA_NN peptidyltransferase_NN region_NN or_CC the_DT deletion_NN mutation_NN in_IN the_DT mtrR_NP promoter_NN region_NN ._SENT The_DT increased_VBN macrolide_NN MICs_NNS for_IN the_DT transformants_NNS remained_VBD unexplained_JJ in_IN this_DT experiment_NN ._SENT The_DT ciprofloxacin-resistant_JJ strain_NN (_( MIC_JJ of_IN 8.0_CD mug/ml_NN )_) used_VBN as_IN a_DT positive_JJ control_NN to_TO transform_VB F62_NP yielded_VBD transformants_NNS with_IN a_DT ciprofloxacin_NN MIC_NN of_IN 2.0_CD mug/ml_NN ._SENT Subsequent_JJ sequencing_VBG of_IN the_DT gyrA_NN and_CC parC_NN genes_NNS of_IN the_DT transformants_NNS revealed_VBD that_IN the_DT mutations_NNS in_IN the_DT transformants_NNS were_VBD identical_JJ to_TO the_DT mutations_NNS of_IN the_DT donor_NN strain_NN (_( gyrA_NN mutations_NNS of_IN 91PHE_NN and_CC 95GLY_JJ and_CC parC_NN mutations_NNS of_IN 86ASN_NP )_) ._SENT Analysis_NN of_IN erythromycin-_NN and_CC azithromycin-resistant_JJ and_CC -susceptible_JJ spontaneous_JJ mutants_NNS ._SENT |_SYM To_TO confirm_VB that_IN the_DT mutations_NNS of_IN rrl_NN were_VBD associated_VBN with_IN macrolide_NN resistance_NN ,_, we_PP attempted_VBD to_TO derive_VB mutants_NNS with_IN reduced_VBN susceptibility_NN from_IN two_CD macrolide-resistant_JJ clinical_JJ isolates_NNS (_( 20869_CD and_CC 20870_CD )_) that_WDT had_VBD mutations_NNS in_IN alleles_NNS 1_CD ,_, 2_CD ,_, and_CC 4_CD of_IN the_DT 23S_JJ rRNA_NN ._SENT Strains_NNS LK368_NP and_CC LK370_NP were_VBD derived_VBN from_IN 20869_CD and_CC 20870_CD ,_, respectively_RB ,_, after_IN subculturing_VBG 35_CD times_NNS on_IN GCMB_NP plates_NNS ._SENT The_DT MICs_NN of_IN erythromycin_NN were_VBD determined_VBN to_TO be_VB 4.0_CD mug/ml_NN for_IN LK368_NP and_CC 32.0_CD to_TO 64.0_CD mug/ml_NN for_IN LK370_NP ,_, and_CC the_DT MICs_NN of_IN azithromycin_NN were_VBD 1.0_CD mug/ml_NN for_IN LK368_NP and_CC 2.0_CD mug/ml_NN for_IN LK370_NP ._SENT Strains_NNS LK368_NP and_CC LK370_NP were_VBD then_RB subcultured_VBN an_DT additional_JJ 12_CD times_NNS on_IN GCMB_NP plates_NNS and_CC yielded_VBD two_CD derivatives_NNS ,_, LK369_NP and_CC LK371_NP ,_, respectively_RB ._SENT The_DT MICs_NN of_IN erythromycin_NN were_VBD determined_VBN to_TO be_VB 2.0_CD mug/ml_NN for_IN LK369_NP and_CC 16.0_CD to_TO 32.0_CD mug/ml_NN for_IN LK371_NP ,_, and_CC the_DT MICs_NN of_IN azithromycin_NN were_VBD 0.5_CD mug/ml_NN for_IN LK369_NP and_CC 2.0_CD to_TO 4.0_CD mug/ml_NN for_IN LK371_NP ._SENT The_DT partial_JJ DNA_NN sequence_NN of_IN 23S_JJ rRNA_NN from_IN these_DT derivatives_NNS showed_VBD that_DT allele_NN 1_CD had_VBD a_DT T->C_NP reversion_NN at_IN nucleotide_NN 2611_CD (_( E._NP coli_NNS numbering_VBG )_) for_IN two_CD strains_NNS ,_, LK368_NP and_CC LK369_NP ,_, and_CC allele_NN 2_CD had_VBD a_DT T->C_NP reversion_NN at_IN nucleotide_NN 2611_CD (_( E._NP coli_NNS numbering_VBG )_) for_IN one_PP strain_VBP only_RB (_( LK369_NP )_) ._SENT The_DT sequences_NNS for_IN alleles_NNS 3_CD and_CC 4_CD remained_VBD identical_JJ to_TO those_DT of_IN the_DT parent_NN strains_NNS ._SENT DNA_NP sequencing_NP of_IN the_DT mtrR_NP repressor_NN promoter_NN region_NN revealed_VBD that_IN the_DT deletion_NN mutation_NN was_VBD not_RB present_JJ ._SENT The_DT two_CD derivatives_NNS (_( LK370_NP and_CC LK371_NP )_) for_IN which_WDT the_DT erythromycin_NN MIC_JJ values_NNS remained_VBD in_IN the_DT range_NN of_IN 16.0_CD to_TO 64.0_CD mug/ml_NN and_CC the_DT azithromycin_NP MICs_NP remained_VBD in_IN the_DT range_NN of_IN 2.0_CD to_TO 4.0_CD mug/ml_NN also_RB retained_VBD the_DT same_JJ DNA_NN sequences_NNS for_IN all_DT four_CD alleles_NNS of_IN the_DT 23S_JJ rRNA_NN as_IN the_DT those_DT of_IN the_DT parent_NN strain_NN ._SENT These_DT derivatives_NNS (_( LK370_NP ,_, LK371_NP ,_, LK368_NP ,_, and_CC LK369_NP )_) did_VBD not_RB show_VB mutations_NNS in_IN the_DT mtrR_NP promoter_NN region_NN ._SENT The_DT resistant-_NN to_TO susceptible-phenotype_NN revertants_NNS showed_VBD the_DT reversion_NN of_IN 23S_JJ rRNA_NN sequence_NN to_TO wild_JJ type_NN and_CC no_DT DNA_NP sequence_NN changes_NNS in_IN the_DT mtrR_NP promoter_NN ._SENT We_PP also_RB attempted_VBD to_TO generate_VB spontaneous_JJ macrolide-resistant_JJ mutants_NNS from_IN susceptible_JJ strains_NNS and_CC compared_VBN the_DT DNA_NN sequences_NNS for_IN the_DT domain_NN V_CD region_NN of_IN the_DT rrl_NN gene_NN ._SENT Three_CD macrolide-susceptible_JJ N._NP gonorrhoeae_NNS strains_NNS ,_, 22831_CD ,_, 21305_CD ,_, and_CC 21855_CD (_( erythromycin_NN MICs_NP ,_, 0.5_CD to_TO 1.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 0.125_CD mug/ml_NN )_) ,_, were_VBD selected_VBN from_IN our_PP$ culture_NN collection_NN ._SENT The_DT sequences_NNS of_IN domain_NN V_NN of_IN rrl_NN of_IN the_DT three_CD strains_NNS (_( 22831_CD ,_, 21305_CD ,_, and_CC 21855_CD )_) were_VBD the_DT same_JJ as_RB that_IN of_IN the_DT susceptible_JJ N._NP gonorrhoeae_NNS reference_NN strain_NN FA1090_NP (_( Gonococcal_NP Genome_NP Sequencing_NP Project_NP ,_, University_NP of_IN Oklahoma_NP )_) ._SENT Initially_RB ,_, six_CD spontaneously_RB resistant_JJ mutants_NNS were_VBD obtained_VBN after_IN subculturing_VBG the_DT three_CD parent_NN strains_NNS 14_CD times_NNS ._SENT Strains_NNS LK359_NP and_CC LK360_NP were_VBD obtained_VBN from_IN parent_NN strain_NN 21855_CD ,_, strains_VBZ LK361_NP and_CC LK362_NP were_VBD from_IN parent_NN strain_NN 22831_CD ,_, and_CC strains_NNS LK363_NP and_CC LK364_NP were_VBD from_IN parent_NN strain_NN 21305_CD ._SENT After_IN subculturing_VBG an_DT additional_JJ nine_CD times_NNS ,_, mutants_NNS LK366_NP and_CC LK367_NP were_VBD obtained_VBN from_IN parent_NN strain_NN 22831_CD ._SENT The_DT MICs_NP and_CC the_DT DNA_NN sequences_NNS of_IN alleles_NNS 1_CD ,_, 2_CD ,_, 3_CD ,_, and_CC 4_CD of_IN the_DT 23S_JJ rRNA_NN of_IN the_DT spontaneous_JJ mutants_NNS and_CC those_DT of_IN their_PP$ parent_NN strains_NNS were_VBD determined_VBN and_CC compared_VBN ._SENT No_DT substitution_NN mutations_NNS were_VBD identified_VBN in_IN any_DT of_IN the_DT four_CD alleles_NNS of_IN the_DT 23S_JJ rRNA_NN of_IN LK361_NP and_CC LK362_NP (_( erythromycin_NN MIC_NP ,_, 8.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 2.0_CD mug/ml_NN )_) ,_, but_CC the_DT alleles_NNS did_VBD have_VB the_DT deletion_NN (_( A_NP )_) in_IN the_DT mtrR_NP promoter_NN region_NN ,_, causing_VBG the_DT formation_NN of_IN mutants_NNS with_IN overexpressed_JJ mtr_NN efflux_NN pumps_NNS ._SENT LK363_NP and_CC LK364_NP (_( erythromycin_NN MIC_NP ,_, 32.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 4.0_CD mug/ml_NN )_) had_VBD the_DT C->T_NP substitution_NN in_IN all_DT four_CD alleles_NNS of_IN the_DT 23S_JJ rRNA_NN ._SENT They_PP did_VBD not_RB have_VB the_DT deletion_NN in_IN the_DT mtrR_NP promoter_NN region_NN ,_, but_CC they_PP did_VBD have_VB an_DT insertion_NN (_( T_NN )_) ._SENT The_DT nucleotide_NN insertion_NN (_( T_NN )_) in_IN the_DT mtrR_NP promoter_NN region_NN was_VBD also_RB identified_VBN in_IN one_CD of_IN the_DT parent_NN strains_NNS ,_, and_CC this_DT mutation_NN did_VBD not_RB seem_VB to_TO confer_VB resistance_NN ._SENT The_DT MICs_NN of_IN erythromycin_NN and_CC azithromycin_NN were_VBD found_VBN to_TO be_VB 64.0_CD mug/ml_NN and_CC 8.0_CD mug/ml_NN ,_, respectively_RB ,_, for_IN strains_NNS LK359_NP and_CC LK360_NP ._SENT These_DT strains_NNS all_RB had_VBD the_DT C->T_NP substitution_NN in_IN all_DT four_CD alleles_NNS of_IN the_DT 23S_JJ rRNA_NN and_CC did_VBD not_RB have_VB the_DT deletion_NN in_IN the_DT mtrR_NP promoter_NN region_NN ._SENT Mutant_JJ LK366_NP had_VBD the_DT C2611T_NP mutation_NN (_( E._NP coli_NNS numbering_VBG )_) in_IN alleles_NNS 1_CD ,_, 2_CD ,_, and_CC 3_CD of_IN the_DT 23S_JJ rRNA_NN ._SENT LK367_JJ had_VBD the_DT C2611T_NP mutation_NN (_( E._NP coli_NNS numbering_VBG )_) in_IN alleles_NNS 1_CD ,_, 2_CD ,_, and_CC 4_CD of_IN the_DT 23S_JJ rRNA_NN ._SENT In_IN comparison_NN with_IN those_DT for_IN the_DT other_JJ mutants_NNS ,_, the_DT MICs_NN of_IN erythromycin_NN (_( 64.0_CD mug/ml_NN )_) and_CC azithromycin_NN (_( 32.0_CD mug/ml_NN )_) were_VBD found_VBN to_TO be_VB the_DT highest_JJS for_IN LK366_NP and_CC LK367_NP ._SENT These_DT strains_NNS (_( LK366_NP and_CC LK367_NP )_) had_VBD mutations_NNS in_IN three_CD of_IN the_DT four_CD alleles_NNS of_IN rrl_NN ,_, while_IN strains_NNS LK359_NP and_CC LK360_NP ,_, for_IN which_WDT azithromycin_NN had_VBD a_DT lower_JJR MIC_NN (_( 8.0_CD mug/ml_NN )_) ,_, had_VBD mutations_NNS in_IN all_DT four_CD alleles_NNS of_IN rrl_NN ._SENT Therefore_RB ,_, the_DT higher_JJR azithromycin_NN MIC_NN does_VBZ not_RB correlate_VB with_IN the_DT number_NN of_IN alleles_NNS with_IN mutations_NNS ._SENT Both_DT LK366_NP and_CC LK367_NP had_VBD one_CD deletion_NN (_( A_NP )_) in_IN the_DT mtrR_NP promoter_NN region_NN which_WDT LK359_NP and_CC LK360_NP did_VBD not_RB have_VB ._SENT This_DT deletion_NN may_MD account_VB for_IN the_DT finding_NN of_IN higher_JJR azithromycin_NN MICs_NNS for_IN LK366_NP and_CC LK367_JJ than_IN for_IN LK359_NP and_CC LK360_NP ,_, which_WDT indicates_VBZ the_DT additive_JJ effects_NNS of_IN multilocus_NN mutations_NNS ._SENT On_IN the_DT other_JJ hand_NN ,_, other_JJ unknown_JJ mechanisms_NNS could_MD also_RB attribute_VB to_TO higher_JJR azithromycin_NN resistance_NN in_IN LK366_NP and_CC LK367_NP ._SENT In_IN conclusion_NN ,_, we_PP have_VBP described_VBN a_DT novel_NN C2611T_NP (_( E._NP coli_NNS numbering_VBG )_) mutation_NN in_IN alleles_NNS 1_CD ,_, 2_CD ,_, and_CC 4_CD in_IN 23S_JJ rRNA_NN that_WDT confers_VBZ macrolide_NN resistance_NN in_IN two_CD clinical_JJ N._NP gonorrhoeae_NNS ._SENT The_DT mtr_NN efflux_NN pump_NN contributes_VBZ to_TO erythromycin_NN resistance_NN in_IN strains_NNS for_IN which_WDT erythromycin_NN MICs_NNS range_VBP from_IN 2.0_CD to_TO 8.0_CD mug/ml_NN and_CC azithromycin_NN MICs_NNS range_VBP from_IN 0.5_CD to_TO 2.0_CD mug/ml_NN ._SENT Higher_JJR levels_NNS of_IN macrolide_NN resistance_NN (_( erythromycin_NN MIC_NP ,_, 16.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 4.0_CD to_TO 8.0_CD mug/ml_NN )_) are_VBP associated_VBN with_IN mutations_NNS of_IN one_CD or_CC more_JJR alleles_NNS of_IN domain_NN V_NN of_IN rrl_NN ._SENT Neither_CC clinical_JJ isolates_NNS nor_CC spontaneous_JJ mutants_NNS in_IN this_DT study_NN showed_VBD that_DT rplD_NN (_( ribosomal_JJ protein_NN L4_NP )_) or_CC rplV_NP (_( ribosomal_JJ protein_NN L22_NP )_) contributed_VBD to_TO resistance_NN ._SENT The_DT spontaneous_JJ mutants_NNS derived_VBN by_IN in_IN vitro_NN mutation_NN to_TO erythromycin_NN resistance_NN revealed_VBD that_IN high-level_JJ macrolide_NN resistance_NN (_( erythromycin_NN MIC_NP ,_, 64.0_CD mug/ml_NN ;_: azithromycin_NP MIC_NP ,_, 32.0_CD mug/ml_NN )_) may_MD require_VB three_CD of_IN the_DT four_CD mutations_NNS in_IN rrl_NN as_RB well_RB as_IN the_DT mutation_NN in_IN the_DT mtr_NN loci_NNS ,_, showing_VBG the_DT additive_JJ effects_NNS of_IN mutations_NNS on_IN resistance_NN levels_NNS ._SENT Although_IN we_PP observed_VBD additive_JJ mechanisms_NNS of_IN macrolide_NN resistance_NN with_IN in_IN vitro_NN mutants_NNS ,_, no_DT clinical_JJ isolates_NNS with_IN both_DT mechanisms_NNS have_VBP yet_RB been_VBN identified_VBN ._SENT This_DT study_NN provided_VBD further_JJR evidence_NN that_IN N._NP gonorrhoeae_NNS is_VBZ evolving_VBG continuously_RB in_IN response_NN to_TO antibiotic_JJ selection_NN pressure_NN ._SENT Characterization_NN of_IN mechanisms_NNS of_IN resistance_NN in_IN these_DT organisms_NNS will_MD provide_VB information_NN necessary_JJ for_IN the_DT development_NN of_IN new_JJ therapies_NNS ._SENT TABLE_NN 2_CD |_SYM Characterization_NN of_IN 14_CD clinical_JJ isolates_NNS of_IN N._NP gonorrhoeae_NNS for_IN which_WDT erythromycin_NN and_CC azithromycin_NN MICs_NNS are_VBP elevated_VBN TABLE_NP 3_CD |_SYM Characterization_NN of_IN spontaneous_JJ N._NP gonorrhoeae_NNS mutants_NNS :_: group_NN I_PP ,_, susceptible_JJ spontaneous_JJ mutants_NNS from_IN erythromycin_NN and_CC azithromycin-resistant_JJ N._NP gonorrhoeae_NNS strains_NNS ;_: group_NN II_NP ,_, erythromycin-_NN and_CC azithromycin-resistant_JJ N._NP gonorrhoeae_NNS mutants_NNS from_IN susceptible_JJ N._NP gonorrhoeae_NNS strains_NNS 